Video
Author(s):
Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.
Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.
Gregory Riely, MD, is a medical oncologist in the Department of Medicine at Memorial Sloan Kettering Cancer Center. Shirish Gadgeel, MD, is the co-leader of the Thoracic Oncology Research Program and a Mary Lou Kennedy Research Professor at the University of Michigan.
Riely and Gadgeel explain their monitoring habits for cardiac-related toxicities with EGFR TKIs. Baseline EKG and echocardiograms are necessary, as are intermittent echocardiograms when patients are on treatment.
As more data become available for patients being treated with the EGFR TKI mobocertinib (Exkivity), it is expected that the overall understanding of cardiac toxicities will be refined. Moreover, patient education is vital for them to understand their symptoms and management options for cardiac toxicities.
42nd Annual CFS Preview for Medical Oncologists: The Show and After Show
Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
2 Commerce Drive
Cranbury, NJ 08512